|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-2-3
|
|
pubmed:abstractText |
Gemcitabine and oxaliplatin have broad antineoplastic activity and favorable toxicity. We conducted a phase I study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of the combination in patients with advanced solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AgelakiSS,
pubmed-author:AndroulakisNN,
pubmed-author:GeorgouliasVV,
pubmed-author:KakolyrisSS,
pubmed-author:KalbakisKK,
pubmed-author:KouroussisCC,
pubmed-author:MarselosMM,
pubmed-author:MavroudisDD,
pubmed-author:NikolaidouMM,
pubmed-author:PappasPP,
pubmed-author:SamonisGG,
pubmed-author:SouglakosJJ,
pubmed-author:VardakisNN
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
304-12
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12562660-Adult,
pubmed-meshheading:12562660-Aged,
pubmed-meshheading:12562660-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12562660-Deoxycytidine,
pubmed-meshheading:12562660-Female,
pubmed-meshheading:12562660-Humans,
pubmed-meshheading:12562660-Infusions, Intravenous,
pubmed-meshheading:12562660-Male,
pubmed-meshheading:12562660-Maximum Tolerated Dose,
pubmed-meshheading:12562660-Middle Aged,
pubmed-meshheading:12562660-Neoplasms,
pubmed-meshheading:12562660-Neutropenia,
pubmed-meshheading:12562660-Organoplatinum Compounds
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
